Research and Markets: Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/261ad4/comparative_analys) has announced the addition of the "Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets" report to their offering.

Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets, which provides insights regarding the comparative analysis of marketed drugs based on safety, efficacy, cost of therapy and total sales revenue. The report also delves deep into the descriptions of every marketed drug, discussing their safety, efficacy, cost of therapy and clinical studies.

Patent Expiries will Intensify the Competition among Generic Players

A patent offers the patentee a monopoly of market exclusivity, and ensures returns on research investments in the absence of competition, therefore encouraging research into novel treatment options.

Patent Expiry of Marketed Drugs in Major Indications, The US, 2011 Note: US - United States, RA - Rheumatoid Arthritis, NSCLC - Non-Small Cell Lung Cancer, PAH - Pulmonary Arterial Hypertension, COPD - Chronic Obstructive Pulmonary Disease, NHL - Non-Hodgkin Lymphoma, GERD - Gastroesophageal Reflux Disease

In dyslipidemia, Lipitor is the world's biggest selling statin drug, with revenue of $11,434m in 2009. It was approved by the US FDA (United States Food and Drug Administration) in 1996. More than half of the antidyslipidemic market is commanded by Lipitor, which is a gold standard therapy. On January 6, 2009, the US Patent and Trademark office reissued a patent to Lipitor that will expire in June 2011. Apotex and Teva are seeking US FDA approval to sell generic versions of Lipitor, and were sued by Pfizer in 2008.

Read more inside Comparative Analysis of Marketed Drugs in Major Indications

For more information visit http://www.researchandmarkets.com/research/261ad4/comparative_analys



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.